1-7 of 7
Paul Roepman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M.L. Jansen, Wendy W.J. de Leng, Maja J.A. de Jonge, Ann Hoeben, Carla M.L. van Herpen, Hans M. Westgeest, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3735–3746.
https://doi.org/10.1158/1078-0432.CCR-24-0011
Published: 03 September 2024
View article titled, Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Open the PDF for Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn, Birgit S. Geurts, Thomas W. Battaglia, Jade M. van Berge Henegouwen, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Myriam Chalabi, Carla M.L. van Herpen, Lot A. Devriese, Frans L.G. Erdkamp, Mariette Labots, Maja J.A. de Jonge, Emile D. Kerver, Adriaan D. Bins, Lindsay V.M. Leek, Jessica C.L. Notohardjo, Alfonsus J.M. van den Eertwegh, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Joris van de Haar, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF13.
https://doi.org/10.1158/1078-0432.CCR-24-0480
Published: 28 August 2024
View article titled, The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Open the PDF for The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Hanneke van der Wijngaart, Louisa R. Hoes, J. Maxime van Berge Henegouwen, Daphne L. van der Velden, Laurien J. Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W.J. de Leng, Anne M.L. Jansen, Niven Mehra, Debbie G.J. Robbrecht, Mariette Labots, Derk Jan A. de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6106–6114.
https://doi.org/10.1158/1078-0432.CCR-21-1104
Published: 15 November 2021
View article titled, Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Open the PDF for Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types in another window
Includes: Supplementary data
Journal Articles

An immune response enriched 72-gene prognostic profile for early stage non-small-cell lung cancer (NSCLC).

Paul Roepman, Nico van Zandwijk
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): PR-5.
Published: 15 August 2014
View article titled, An immune response enriched 72-gene prognostic profile for early stage non-small-cell lung cancer (NSCLC).
Journal Articles

Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer

Paul Roepman, Hugo M. Horlings, Oscar Krijgsman, Marleen Kok, Jolien M. Bueno-de-Mesquita, Richard Bender, Sabine C. Linn, Annuska M. Glas, Marc J. van de Vijver
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7003–7011.
https://doi.org/10.1158/1078-0432.CCR-09-0449
Published: 11 November 2009
View article titled, Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
Open the PDF for Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer in another window
Journal Articles

An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer

Paul Roepman, Jacek Jassem, Egbert F. Smit, Thomas Muley, Jacek Niklinski, Tony van de Velde, Anke T. Witteveen, Witold Rzyman, Arno Floore, Sjaak Burgers, Giuseppe Giaccone, Michael Meister, Hendrik Dienemann, Marcin Skrzypski, Miroslaw Kozlowski, Wolter J. Mooi, Nico van Zandwijk
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 284–290.
https://doi.org/10.1158/1078-0432.CCR-08-1258
Published: 31 December 2008
View article titled, An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer
Open the PDF for An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer in another window
Includes: Supplementary data